HUP0300923A3 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras - Google Patents

Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Info

Publication number
HUP0300923A3
HUP0300923A3 HU0300923A HUP0300923A HUP0300923A3 HU P0300923 A3 HUP0300923 A3 HU P0300923A3 HU 0300923 A HU0300923 A HU 0300923A HU P0300923 A HUP0300923 A HU P0300923A HU P0300923 A3 HUP0300923 A3 HU P0300923A3
Authority
HU
Hungary
Prior art keywords
ras
angiogenesis
modulation
methods
protein kinase
Prior art date
Application number
HU0300923A
Other languages
English (en)
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HUP0300923A2 publication Critical patent/HUP0300923A2/hu
Publication of HUP0300923A3 publication Critical patent/HUP0300923A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HU0300923A 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras HUP0300923A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14892499P 1999-08-13 1999-08-13
US21595100P 2000-07-05 2000-07-05
PCT/US2000/021842 WO2001012210A1 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase raf and ras

Publications (2)

Publication Number Publication Date
HUP0300923A2 HUP0300923A2 (hu) 2003-07-28
HUP0300923A3 true HUP0300923A3 (en) 2005-12-28

Family

ID=26846311

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300923A HUP0300923A3 (en) 1999-08-13 2000-08-11 Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras

Country Status (17)

Country Link
US (1) US20060040853A1 (hu)
EP (1) EP1210099A4 (hu)
JP (1) JP2003507337A (hu)
KR (2) KR100759241B1 (hu)
CN (1) CN1208087C (hu)
AU (1) AU781877B2 (hu)
BR (1) BR0013228A (hu)
CA (1) CA2380966A1 (hu)
CZ (1) CZ2002449A3 (hu)
HK (1) HK1050856A1 (hu)
HU (1) HUP0300923A3 (hu)
MX (1) MXPA02001553A (hu)
NO (1) NO20020718L (hu)
PL (1) PL364928A1 (hu)
RU (1) RU2257911C2 (hu)
SK (1) SK2142002A3 (hu)
WO (1) WO2001012210A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223571A1 (en) * 2000-09-29 2002-04-08 Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
DK2152701T3 (en) * 2007-03-12 2016-02-15 Ym Biosciences Australia Pty Phenylaminopyrimidinforbindelser and uses thereof
EP2235189A1 (en) 2008-01-14 2010-10-06 Genentech, Inc. Methods for inhibiting angiogenesis using egfl8 antagonists
EP2329854A3 (de) * 2009-12-04 2014-02-19 Biotronik VI Patent AG Implantatbeschichtung mit Nukleinsäuren
CN102766601B (zh) * 2011-11-17 2015-12-16 中山大学肿瘤防治中心 含有可诱导型癌基因的细胞系及其建立方法、应用
RU2662781C2 (ru) * 2014-06-03 2018-07-30 Эррера Артуро Солис Животные модели ангиогенеза роговицы и эктазированных состояний роговицы, их способы получения и способы применения
RU2728870C2 (ru) * 2017-10-12 2020-07-31 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Полипептиды для лечения онкологических заболеваний
WO2021211784A2 (en) * 2020-04-15 2021-10-21 Cohbar, Inc. Method of treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156841A (en) * 1988-08-26 1992-10-20 United States Of America Anti-tumor vaccine
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5597719A (en) 1994-07-14 1997-01-28 Onyx Pharmaceuticals, Inc. Interaction of RAF-1 and 14-3-3 proteins
US5795910A (en) * 1994-10-28 1998-08-18 Cor Therapeutics, Inc. Method and compositions for inhibiting protein kinases
US6300081B1 (en) * 1996-11-15 2001-10-09 Cornell Research Foundation, Inc. Activated ras interaction assay
US6376471B1 (en) * 1997-10-10 2002-04-23 Johns Hopkins University Gene delivery compositions and methods

Also Published As

Publication number Publication date
HK1050856A1 (en) 2003-07-11
BR0013228A (pt) 2003-06-17
KR20020032553A (ko) 2002-05-03
WO2001012210A1 (en) 2001-02-22
MXPA02001553A (es) 2003-05-23
AU6763300A (en) 2001-03-13
KR100805098B1 (ko) 2008-02-20
HUP0300923A2 (hu) 2003-07-28
US20060040853A1 (en) 2006-02-23
PL364928A1 (en) 2004-12-27
CZ2002449A3 (cs) 2002-08-14
NO20020718D0 (no) 2002-02-12
WO2001012210A9 (en) 2002-09-12
CA2380966A1 (en) 2001-02-22
AU781877B2 (en) 2005-06-16
KR100759241B1 (ko) 2007-09-18
CN1208087C (zh) 2005-06-29
JP2003507337A (ja) 2003-02-25
NO20020718L (no) 2002-04-10
EP1210099A4 (en) 2006-01-18
KR20070067210A (ko) 2007-06-27
RU2257911C2 (ru) 2005-08-10
SK2142002A3 (en) 2002-07-02
EP1210099A1 (en) 2002-06-05
CN1378457A (zh) 2002-11-06

Similar Documents

Publication Publication Date Title
HK1244797A1 (zh) 環蛋白酪氨酸激酶抑制劑
HUS1700048I1 (hu) Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai
HUP0103520A3 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them
HK1172504A1 (en) Composition and methods for modulation of vascular structure and or function
EP1203092A4 (en) ANTISENSE MODULATION OF THE MAP KINASE KINASE 6 EXPRESSION
AU4065000A (en) Antisense modulation of p38 mitogen activated protein kinase expression
HUP0203323A3 (en) Tyrosine kinase inhibitors and pharmaceutical compositions containing them
NO20021382L (no) Fremgangsmåter og mikroorganismer for fremstilling av panto- forbindelser
IL158588A0 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl) - methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinase inhibitors
IL137041A0 (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
IL148803A0 (en) Novel composition and method for stabilizing the same
IL139583A0 (en) Natural source compositions for the control of post-harvest pathologies and method of application
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
NO20012963L (no) Fremgangsmåte for fremstilling av 3-alkanoylindoler og 3- alkylindoler
HK1050856A1 (en) Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras
HUP0102614A3 (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src
AU6137801A (en) Method and composition for the treatment of angiogenesis
IL161057A0 (en) Composition and method for minimizing or avoiding adverse effects of vesicants
AU2876000A (en) Tyrosine kinase inhibitors and methods of using the same
AU2003297554A8 (en) Modulation of death-associated protein kinase 1 expression
AU2002348191A1 (en) Method and composition for the modulation of angiogenesis
IL146505A (en) Methods for the preparation of tetrahydroisoquinolinephenol derivatives and some new such derivatives
AU2002353074A8 (en) Antisense modulation of pctaire protein kinase 1 expression
AU2404500A (en) Compositions and methods for stabilizing thiol-containing biomolecules
GB9904392D0 (en) Compositions and methods for monitoring the modification of natural binding partners

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees